Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UNIPROT:P00790 (
PGA
)
2,475
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
A study involving results of the
PGA
Tour, Senior
PGA
Tour, and the LPGA Tour investigated whether "choking under pressure" occurs among professional golfers. Players were individuals who either were leading going into the final round or within five strokes of the lead. It was hypothesized that players who were one
stroke
from the lead and to a lesser extent players who were leading should have higher final round scores than those players who were two or more strokes from the lead ("choking"). However, the results did not support the choking hypothesis. Players who were leading going into the final round won the majority of the time.
...
PMID:Do professional golfers "choke"? 1218 33
Prostaglandins (PGs) originate from the degradation of membranar arachidonic acid by cyclooxygenases (COX-1 and COX-2). The prostaglandin actions in the nervous system are multiple and have been suggested to play a significant role in neurodegenerative disorders. Some PGs have been reported to be toxic and, interestingly, the cyclopentenone PGs have been reported to be cytoprotective at low concentration and could play a significant role in neuronal plasticity. They have been shown to be protective against oxidative stress injury; however, the cellular mechanisms of protection afforded by these PGs are still unclear. It is postulated that the cascade leading to neuronal cell death in acute and chronic neurodegenerative conditions, such as cerebral ischemia and Alzheimer's disease, would be mediated by free radical damage. We tested the hypothesis that the neuroprotective action of cyclopentanone could be caused partially by an induction of heme oxygenase 1 (HO-1). We and others have previously reported that modulation of HO total activity may well have direct physiological implications in
stroke
and in Alzheimer's disease. HO acts as an antioxidant enzyme by degrading heme into iron, carbon monoxide, and biliverdin that is rapidly converted into bilirubin. Using mouse primary neuronal cultures, we demonstrated that PGs of the J series induce HO-1 in a dose-dependent manner (0, 0.5, 5, 10, 20, and 50 micro g/ml) and that PGJ(2) and dPGJ(2) were more potent than
PGA
(2), dPGA(2), PGD(2), and PGE(2). No significant effects were observed for HO-2 and actin expression. In regard to HO-3 expression found in rat, with its protein deducted sequence highly homologous to HO-2, no detection was observed in HO-2(-/-) mice, suggesting that HO-3 protein would not be present in mouse brain. We are proposing that several of the protective effects of PGJ(2) could be mediated through beneficial actions of heme degradation and its metabolites. The design of new mimetics based on the cyclopentenone structure could be very useful as neuroprotective agents and be tested in animal models of
stroke
and Alzheimer's disease.
...
PMID:Regulation of heme oxygenase expression by cyclopentenone prostaglandins. 1270 76
Both prostaglandin A(1) (
PGA
(1)) and lithium have been reported to protect neurons against excitotoxic and ischemic injury. The present study was undertaken to examine the effects of lithium and PGA1 on heat shock proteins (HSP) and the growth arrest and DNA-damage-inducible gene (GADD153) and to evaluate if lithium could potentiate
PGA
(1)'s neuroprotective effects against cerebral ischemia. Rats were pretreated with a subcutaneous injection of lithium for 2 days and a single intracerebral ventricle administration of
PGA
(1) 15 min before ischemic insult. Brain ischemia was induced by a permanent middle cerebral artery occlusion. The infarct volume, motor behavior deficits and brain edema were analyzed 24 h after ischemic insult. The result showed that
PGA
(1) significantly reduced infarct volume, neurological deficits and brain edema. Except for neurological deficit, lithium enhanced
PGA
(1)'s neuroprotection. The neuroprotective effects of
PGA
(1) were associated with an up-regulation of cytoprotective heat shock proteins HSP70 and GRP78 in the ischemic brain hemisphere as determined by immunoblotting and immunofluorescence. The induction of HSP70 and GRP78 was enhanced by lithium. However, although the expression of GADD153 was enhanced significantly after pMCAO, it was not influenced by either
PGA
(1) or lithium or their combination. These studies suggest that lithium can potentiate
PGA
(1)'s neuroprotective effects and thus may have potential clinical value for the treatment of
stroke
in combination with other neuroprotective agents.
...
PMID:Enhancement of neuroprotection and heat shock protein induction by combined prostaglandin A1 and lithium in rodent models of focal ischemia. 1679 96
This case study examined the effects of a clutch-based hypnotic intervention on the performance and experience of a senior
PGA
tour golfer. The intervention encompassed hypnosis, regression imagery, a trigger control technique, and a preshot routine. Golf performance data were analyzed using a single-subject design. The results indicated that the player's mean
stroke
average decreased from baseline to postintervention. The qualitative data suggests that the hypnotic intervention may help golfers regulate emotions, thoughts, feelings, and perceptions associated with a clutch state experience.
...
PMID:Clutch-Based Hypnotic Intervention to Improve Golf Performance: A Case Study. 3314 24